AAPL337.00+4.59 (+1.38%) ▲|ABBV264.02+1.51 (+0.58%) ▲|ABT102.23-0.13 (-0.13%) ▼|ACN190.29+0.65 (+0.34%) ▲|ADBE252.67+2.17 (+0.87%) ▲|AMAT417.40+2.02 (+0.49%) ▲|AMD545.09+32.59 (+6.36%) ▲|AMGN379.78+3.43 (+0.91%) ▲|AMT175.58-0.81 (-0.46%) ▼|AMZN251.19+5.23 (+2.13%) ▲|AVGO347.30+7.79 (+2.29%) ▲|AXP311.17-1.26 (-0.40%) ▼|BA197.00-4.96 (-2.46%) ▼|BAC58.18+0.28 (+0.48%) ▲|BKNG170.52-0.88 (-0.51%) ▼|BLK1,053.96+16.72 (+1.61%) ▲|BMY62.84-0.76 (-1.20%) ▼|BNY153.02-0.45 (-0.29%) ▼|BRK-B509.20-10.60 (-2.04%) ▼|C132.70-0.25 (-0.19%) ▼|CAT798.57+15.85 (+2.03%) ▲|CL87.73+0.71 (+0.82%) ▲|CMCSA22.91-0.82 (-3.46%) ▼|COF202.04-1.15 (-0.57%) ▼|COP133.19+0.65 (+0.49%) ▲|COST893.93+0.19 (+0.02%) ▲|CRM242.85-7.25 (-2.90%) ▼|CSCO110.24+2.50 (+2.32%) ▲|CVS90.27-1.45 (-1.58%) ▼|CVX211.57+0.03 (+0.01%) ▲|DE685.63+16.16 (+2.41%) ▲|DHR212.50+4.14 (+1.99%) ▲|DIS105.35-1.64 (-1.53%) ▼|DUK118.54+0.78 (+0.66%) ▲|EMR147.40+1.57 (+1.08%) ▲|FDX305.88+4.16 (+1.38%) ▲|GD355.95-4.05 (-1.13%) ▼|GE313.47+0.57 (+0.18%) ▲|GEV924.93-0.16 (-0.02%) ▼|GILD150.89+3.21 (+2.17%) ▲|GM86.62+2.33 (+2.76%) ▲|GOOG343.68+4.32 (+1.27%) ▲|GOOGL347.33+4.46 (+1.30%) ▲|GS951.47+13.49 (+1.44%) ▲|HD302.51+0.04 (+0.01%) ▲|HON206.49-1.17 (-0.56%) ▼|IBM237.75+0.26 (+0.11%) ▲|INTC108.80+7.75 (+7.67%) ▲|INTU313.13-5.00 (-1.57%) ▼|ISRG383.54+1.25 (+0.33%) ▲|JNJ270.22+2.94 (+1.10%) ▲|JPM349.31+0.39 (+0.11%) ▲|KO88.06+0.19 (+0.22%) ▲|LIN458.48-3.61 (-0.78%) ▼|LLY1,152.44+14.62 (+1.28%) ▲|LMT538.09+0.84 (+0.16%) ▲|LOW194.19+0.09 (+0.05%) ▲|LRCX269.31+0.08 (+0.03%) ▲|MA565.73-2.02 (-0.36%) ▼|MCD248.48-0.08 (-0.03%) ▼|MDLZ62.04-0.32 (-0.51%) ▼|MDT92.77+0.17 (+0.18%) ▲|META682.31+9.00 (+1.34%) ▲|MMM164.71+2.06 (+1.27%) ▲|MO69.70-0.40 (-0.57%) ▼|MRK147.15+2.24 (+1.55%) ▲|MS203.52+1.10 (+0.54%) ▲|MSFT497.75+7.45 (+1.52%) ▲|MU977.50+50.95 (+5.50%) ▲|NEE81.28+0.91 (+1.13%) ▲|NFLX75.31-1.10 (-1.44%) ▼|NKE36.36+0.58 (+1.62%) ▲|NOW138.47-1.35 (-0.97%) ▼|NVDA219.34+5.44 (+2.54%) ▲|ORCL150.59+7.43 (+5.19%) ▲|PEP133.66-0.68 (-0.51%) ▼|PFE27.64+0.18 (+0.66%) ▲|PG147.55+0.53 (+0.36%) ▲|PLTR176.24+1.90 (+1.09%) ▲|PM190.48-1.23 (-0.64%) ▼|QCOM188.71+3.87 (+2.09%) ▲|RTX193.54-3.29 (-1.67%) ▼|SBUX96.67-0.67 (-0.69%) ▼|SCHW104.63-0.53 (-0.50%) ▼|SO86.76+0.53 (+0.61%) ▲|SPG204.47+1.53 (+0.75%) ▲|T25.39-0.47 (-1.82%) ▼|TMO658.32+9.89 (+1.53%) ▲|TMUS166.45-9.81 (-5.57%) ▼|TSLA366.20+8.12 (+2.27%) ▲|TXN258.14-2.53 (-0.97%) ▼|UBER70.87-0.10 (-0.14%) ▼|UNH375.21-0.05 (-0.01%) ▼|UNP282.48+1.56 (+0.56%) ▲|UPS100.17+1.40 (+1.42%) ▲|USB60.25+0.52 (+0.87%) ▲|V369.93-1.00 (-0.27%) ▼|VZ48.33-1.43 (-2.87%) ▼|WFC86.89-0.16 (-0.18%) ▼|WMT106.79-0.71 (-0.66%) ▼|XOM163.27-0.05 (-0.03%) ▼|AAPL337.00+4.59 (+1.38%) ▲|ABBV264.02+1.51 (+0.58%) ▲|ABT102.23-0.13 (-0.13%) ▼|ACN190.29+0.65 (+0.34%) ▲|ADBE252.67+2.17 (+0.87%) ▲|AMAT417.40+2.02 (+0.49%) ▲|AMD545.09+32.59 (+6.36%) ▲|AMGN379.78+3.43 (+0.91%) ▲|AMT175.58-0.81 (-0.46%) ▼|AMZN251.19+5.23 (+2.13%) ▲|AVGO347.30+7.79 (+2.29%) ▲|AXP311.17-1.26 (-0.40%) ▼|BA197.00-4.96 (-2.46%) ▼|BAC58.18+0.28 (+0.48%) ▲|BKNG170.52-0.88 (-0.51%) ▼|BLK1,053.96+16.72 (+1.61%) ▲|BMY62.84-0.76 (-1.20%) ▼|BNY153.02-0.45 (-0.29%) ▼|BRK-B509.20-10.60 (-2.04%) ▼|C132.70-0.25 (-0.19%) ▼|CAT798.57+15.85 (+2.03%) ▲|CL87.73+0.71 (+0.82%) ▲|CMCSA22.91-0.82 (-3.46%) ▼|COF202.04-1.15 (-0.57%) ▼|COP133.19+0.65 (+0.49%) ▲|COST893.93+0.19 (+0.02%) ▲|CRM242.85-7.25 (-2.90%) ▼|CSCO110.24+2.50 (+2.32%) ▲|CVS90.27-1.45 (-1.58%) ▼|CVX211.57+0.03 (+0.01%) ▲|DE685.63+16.16 (+2.41%) ▲|DHR212.50+4.14 (+1.99%) ▲|DIS105.35-1.64 (-1.53%) ▼|DUK118.54+0.78 (+0.66%) ▲|EMR147.40+1.57 (+1.08%) ▲|FDX305.88+4.16 (+1.38%) ▲|GD355.95-4.05 (-1.13%) ▼|GE313.47+0.57 (+0.18%) ▲|GEV924.93-0.16 (-0.02%) ▼|GILD150.89+3.21 (+2.17%) ▲|GM86.62+2.33 (+2.76%) ▲|GOOG343.68+4.32 (+1.27%) ▲|GOOGL347.33+4.46 (+1.30%) ▲|GS951.47+13.49 (+1.44%) ▲|HD302.51+0.04 (+0.01%) ▲|HON206.49-1.17 (-0.56%) ▼|IBM237.75+0.26 (+0.11%) ▲|INTC108.80+7.75 (+7.67%) ▲|INTU313.13-5.00 (-1.57%) ▼|ISRG383.54+1.25 (+0.33%) ▲|JNJ270.22+2.94 (+1.10%) ▲|JPM349.31+0.39 (+0.11%) ▲|KO88.06+0.19 (+0.22%) ▲|LIN458.48-3.61 (-0.78%) ▼|LLY1,152.44+14.62 (+1.28%) ▲|LMT538.09+0.84 (+0.16%) ▲|LOW194.19+0.09 (+0.05%) ▲|LRCX269.31+0.08 (+0.03%) ▲|MA565.73-2.02 (-0.36%) ▼|MCD248.48-0.08 (-0.03%) ▼|MDLZ62.04-0.32 (-0.51%) ▼|MDT92.77+0.17 (+0.18%) ▲|META682.31+9.00 (+1.34%) ▲|MMM164.71+2.06 (+1.27%) ▲|MO69.70-0.40 (-0.57%) ▼|MRK147.15+2.24 (+1.55%) ▲|MS203.52+1.10 (+0.54%) ▲|MSFT497.75+7.45 (+1.52%) ▲|MU977.50+50.95 (+5.50%) ▲|NEE81.28+0.91 (+1.13%) ▲|NFLX75.31-1.10 (-1.44%) ▼|NKE36.36+0.58 (+1.62%) ▲|NOW138.47-1.35 (-0.97%) ▼|NVDA219.34+5.44 (+2.54%) ▲|ORCL150.59+7.43 (+5.19%) ▲|PEP133.66-0.68 (-0.51%) ▼|PFE27.64+0.18 (+0.66%) ▲|PG147.55+0.53 (+0.36%) ▲|PLTR176.24+1.90 (+1.09%) ▲|PM190.48-1.23 (-0.64%) ▼|QCOM188.71+3.87 (+2.09%) ▲|RTX193.54-3.29 (-1.67%) ▼|SBUX96.67-0.67 (-0.69%) ▼|SCHW104.63-0.53 (-0.50%) ▼|SO86.76+0.53 (+0.61%) ▲|SPG204.47+1.53 (+0.75%) ▲|T25.39-0.47 (-1.82%) ▼|TMO658.32+9.89 (+1.53%) ▲|TMUS166.45-9.81 (-5.57%) ▼|TSLA366.20+8.12 (+2.27%) ▲|TXN258.14-2.53 (-0.97%) ▼|UBER70.87-0.10 (-0.14%) ▼|UNH375.21-0.05 (-0.01%) ▼|UNP282.48+1.56 (+0.56%) ▲|UPS100.17+1.40 (+1.42%) ▲|USB60.25+0.52 (+0.87%) ▲|V369.93-1.00 (-0.27%) ▼|VZ48.33-1.43 (-2.87%) ▼|WFC86.89-0.16 (-0.18%) ▼|WMT106.79-0.71 (-0.66%) ▼|XOM163.27-0.05 (-0.03%) ▼|
25.2 C
New York
Friday, September 18, 2026

Tag: press release

New York Mortgage Trust Declares Second Quarter 2025 Common Stock Dividend of $0.20 Per Share, and Preferred Stock Dividends

NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- New York Mortgage Trust, Inc. (Nasdaq: NYMT) (the “Company”) announced today that its Board of Directors (the “Board”) declared a regular quarterly cash dividend of $0.20 per share on shares of its common stock for the quarter ending June 30, 2025. The dividend will be payable on July 30, 2025 to common stockholders of record as of the close of business on June 23, 2025.

American Outdoor Brands Fourth Quarter and Full Year Fiscal 2025 Financial Release and Conference Call Alert

COLUMBIA, Mo., June 12, 2025 /PRNewswire/ -- American Outdoor Brands, Inc. (NASDAQ Global Select: AOUT), an innovation company that provides product solutions for outdoor...

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment

PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study’s lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial’s second active clinical site.

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities

Matt Morgan Joins Netcapital Crypto Advisory Board

BOSTON, MA, June 12, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, today announced that Matt Morgan has joined the Company’s newly established Crypto Advisory Board.

Primis Financial Corp. Announces Signed Term Sheet to Sell a Portion of its Shares of Panacea Financial Holdings, Inc.

MCLEAN, Va., June 12, 2025 /PRNewswire/ -- Primis Financial Corp. (NASDAQ: FRST) ("Primis" or the "Company") today reported a signed non-binding term sheet to...

Semiconductor Devices for High-Temperature Applications: Revolutionizing Advanced Technology Markets

"In-Depth Analysis of the Market for Semiconductor Devices for High-Temperature Applications: Highlighting Segmentation by Material, Device Type, Operating Temperature, and Industry, Offering Insights into...

Catheter Precision, Inc. Comments on Recent Market Activity

FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, is issuing this press release in response to recent increases in trading activity in its common stock. The Company is not aware of any information related to the Company or its operations that it would have expected to cause increased market activity. The Company continues to pursue its strategic plans as previously disclosed, including its ongoing efforts to secure financing to meet its liquidity needs.

DarkPulse, Inc. Contracts Kraken International Security Solutions LLC as Part of its Border and Perimeter Security Initiatives

Kraken’s Founder Mr. Boone Smith’s extensive experience and work at U.S. Dept of Homeland Security and U.S. Customs and Border Protection adds the necessary team capabilities to assist the Company’s border security solutions effort
Kraken’s Founder Mr. Boone Smith’s extensive experience and work at U.S. Dept of Homeland Security and U.S. Customs and Border Protection adds the necessary team capabilities to assist the Company’s border security solutions effort

Heritage Distilling Delivers Cryptocurrency Remarks at Summit Investor Conference

Heritage Distilling Delivers Cryptocurrency Remarks at Summit Investor Conference

DeFi Development Corp. to Host Twitter Spaces Explaining ELOCs, S-1s, and Capital Strategy

BOCA RATON, FL, June 12, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first U.S. public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today it will host a live Twitter Spaces event on Monday, June 16, 2025 at 1:00 PM ET to walk investors through the company’s recent S-1 filings, its newly announced $5 billion Equity Line of Credit (ELOC), and broader public market capital strategy.

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPress release